Case Study

International Journal of Current Innovations in Advanced Research

Available at www.ijciar.com ISSN (O) 2636-6282 ISSN (P) 2659-1553

Case Study: Guillain-Barré Syndrome (GBS)

S. Arun Sathya Dev[1], M.Roja[2], L.Satish Kumar Achari[2]

[1] Professor, Department of Pharmaceutical Chemistry, Avanthi Institute of Pharmaceutical Sciences

[2] Avanthi Institute of Pharmaceutical Sciences, Tagarapuvalasa, Andhra Pradesh, India.

Corresponding Author

L.Satish Kumar Achari

Received: 22 Jan 2022 Revised: 02 Feb 2022 Accepted: 28 Mar 2022

Abstract

Guillain-Barré Syndrome (GBS) is a rare autoimmune disorder characterized by progressive muscle weakness, paralysis, and in severe cases, respiratory failure. This case study provides an in-depth analysis of a patient diagnosed with Guillain-Barré Syndrome, focusing on clinical presentation, diagnostic challenges, treatment modalities, and the patient's management journey.

Keywords: Guillain-Barré Syndrome, paralysis, respiratory failure.

Introduction

Guillain-Barré Syndrome is a rare autoimmune disorder affecting the peripheral nervous system, characterized by rapid onset muscle weakness, numbness, and, in severe cases, paralysis. It is characterized by the immune system's abnormal response, where it mistakenly attacks healthy nerve cells, leading to nerve inflammation and subsequent muscle weakness or paralysis. Named after the French neurologists Georges Guillain and Jean Alexandre Barré, who first described the condition in the early 20th century, GBS often develops following a viral or bacterial infection [1].

The syndrome typically begins with symptoms such as tingling sensations, numbness, or weakness in the legs, which then progressively spread to the arms and upper body. In severe cases, GBS can cause paralysis of the entire body, including muscles responsible for breathing. The onset of symptoms can be rapid, evolving over a few hours to days, making it a medical emergency in some instances [3].

The exact cause of Guillain-Barré syndrome remains unclear, but it is believed to involve an immune system malfunction triggered by infections like Campylobacter jejuni (a bacteria often linked to food poisoning), cytomegalovirus, Epstein-Barr virus, or Zika virus. The immune system's attack damages the protective myelin sheath covering the nerves, disrupting the transmission of signals between the brain, spinal cord, and the rest of the body [5].

Treatment for GBS typically involves hospitalization to monitor and manage symptoms. Intravenous immunoglobulin (IVIG) therapy or plasmapheresis, a process that filters the blood to remove harmful antibodies, are common treatment to reduce the severity and duration of the illness [4]. While most individuals with Guillain-Barré syndrome recover with proper medical care and rehabilitation, some may experience residual weakness or neurological deficits.



Case Presentation

A 45-year-old male presented with a sudden onset of ascending weakness in the lower limbs, accompanied by tingling sensations and difficulty in walking. Over the subsequent days, the weakness progressed to involve the upper limbs and eventually led to respiratory muscle involvement, requiring mechanical ventilation. The clinical examination revealed areflexia and sensory deficits. Electrophysiological studies demonstrated features consistent with demyelinating polyneuropathy, supporting the diagnosis of Guillain-Barré Syndrome.

Pathophysiology

The case study delves into the pathophysiological mechanisms underlying GBS, emphasizing the role of molecular mimicry, where an immune response to an infection cross-reacts with peripheral nerve components, leading to demyelination or axonal damage. The involvement of molecular targets such as gangliosides and the immune response mediated by T-cells and antibodies is discussed [2].



Diagnostic Approaches

Diagnostic procedures including nerve conduction studies, cerebrospinal fluid analysis revealing elevated protein levels with a normal cell count (albuminocytologic dissociation), and clinical criteria help confirm the diagnosis of Guillain-Barré Syndrome. The importance of a thorough clinical history and the exclusion of other neurological conditions with similar presentations are highlighted.

Treatment and Management

The patient received intravenous immunoglobulin (IVIG) therapy promptly upon diagnosis. The case study discusses the rationale behind IVIG as the standard treatment for GBS, its mechanism of action, and the management of complications such as autonomic dysfunction and respiratory failure. Rehabilitation interventions aimed at optimizing the patient's recovery and improving functional outcomes are also detailed.

Patient Outcomes and Follow-Up

The patient showed gradual improvement in muscle strength following IVIG therapy and physiotherapy sessions. Long-term follow-up for monitoring residual neurological deficits, functional rehabilitation, and the potential for relapses or residual symptoms is emphasized.

Conclusion

In conclusion, this case study highlights the clinical manifestations, diagnostic considerations, treatment modalities, and management approach for Guillain-Barré Syndrome. It emphasizes the importance of early recognition, prompt intervention, and comprehensive care to optimize outcomes for patients affected by this challenging neurological condition.

Ethical Approval

This study received support from King George Hospital, Vizianagaram.

Acknowledgment

We acknowledge the continuous support from the H.O.D of the general medicine department superintendent of King George Hospital [KGH] for completing the study.

References

1. Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012 Jun 14;366(24):2294-304. [PubMed]
2. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014 Jan;137(Pt 1):33-43. [PubMed]
3. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016 Aug 13;388(10045):717-27. [PubMed]
4. Hughes RA, Cornblath DR. Guillain-Barré syndrome. *Lancet* 2005;366:1653–66. [PubMed] [Google Scholar]
5. Ortiz-Salas P, Velez-Van-Meerbeke A, Galvis-Gomez CA, Rodriguez Q JH. Human Immunoglobulin Versus Plasmapheresis in Guillain-Barre Syndrome and Myasthenia Gravis: A Meta-Analysis. J Clin Neuromuscul Dis. 2016 Sep;18(1):1-11. [PubMed] [Reference list]